RomiCar: Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma

Change of Staff

If there is a change of staff working on the trial please print off and complete the relevant registration form below. Please also ensure that the Signature and Delegation Log is updated. 

Trial Documents

Links to the current protocol, Patient Information Sheet, Informed Consent Form are provided below. If there has been a recent amendment to the trial please ensure you have R&D approval before using these documents.

Other documents (e.g. Amendments, Case Report Form, Serious Adverse Event Form, Guidelines, GP Letter, Release of Medical Information Form etc) can be found by clicking on the other menu items below. If you cannot find what you are looking for please contact the RomiCar Trial Office.

Version Control Lists

The version numbers and dates of all documents used for the trial are captured on a Version Control List. Links to the Version Control Lists used in this trial are below in reverse date order.




Below is a link to a document which lists all of the substantial protocol amendments which have been made for this trial. The folders below contain the relevant amended documentation and approval letters. Please ensure that you have R&D approval (if applicable) before using the latest versions of these documents.


Other Trial Documents


To date there are no publications for this trial.

News and Events

RomiCar newsletters

Contact Details

Chief Investigator
Graham Collins

Consultant Haematologist, Honorary Senior Clinical Lecturer in Haematology

Oxford Cancer and Haematology Centre, Churchill Hospital, Old Road,Oxford, OX3 7EJ

Tel:      +44 (0) 1865 235886
Fax:     +44 (0) 1865 235260

RomiCar Trial Office
Trial Coordinator:                                Eszter Nagy               
Trial Monitor:                                       Poonam Patel          
Trial Management Team Leader:       Shamyla Siddique
Trial Statistician:                                 Kristian Brock

Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
B15 2TT

Telephone: +44 (0)121 414 7673
Fax:             +44 (0)121 414 6061

Trial Entry
Telephone:0121 414 7673                                                               (9.00 am till 5.00 pm Monday to Friday)

Serious Adverse Event Reporting
Fax: 0121 414 6061                                                 or                                                0121 414 3700

Sponsor  University of Birmingham